GSK shingles shot might trump Merck's Zostavax, analysts say

Though GlaxoSmithKline ($GSK) is still waiting on late-stage results from its shingles vaccine, HZ/su, Cowen & Co. analysts say the GSK shot may just be better than Merck's Zostavax. The deciding factor? An advantage for HZ/su in older people, the analysts said. More from FierceVaccines